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Abstract 
Background: Lung cancer is the leading cause of cancer-related deaths worldwide, and treatments for lung cancer 
have a high failure rate. Anti-angiogenic therapy is also often ineffective because of refractory disease. Endostatin (ES) 
is one of the most widely-used anti-angiogenic drugs for lung cancer in China, and resistance to it is a barrier that 
needs to be resolved. It has been shown that myeloid-derived suppressor cells (MDSCs) are involved in resistance 
to ES. Whether other cells and/or cell factors in the tumor microenvironment that have been shown to be related to 
resistance to other anti-cancer drugs are also involved in ES resistance is unknown.
Results: In this study, we showed that after continuously treatment with ES for 12 days, volumes of A549 transplan-
tation tumors of mice reached the sizes of tumors which were borne by mice that were treated with normal saline 
and this meant that resistance to ES appeared. Cancer stem cells (CSCs), which have been widely accepted as one of 
reasons responsible for resistance to many anti-tumor drugs were also being discovered increased proportionally in 
A549 transplantation tumors after ES treatment for 12 days. During further exploration of reasons for this increase, we 
discovered that after ES treatment, microvessel density and vascular endothelial growth factor level was decreased in 
tumors, whereas transforming growth factor (TGF)-β1 level was elevated, and MDSCs, one of the sources of TGF-β1, 
were also increased. We speculate that hypoxia and TGF-β1 are responsible for the increased CSC number in A549 
transplantation tumors. By using cobalt chloride to mimic hypoxia and human recombinant TGF-β1 in vitro, we found 
that hypoxia and TGF-β1can indeed enhance the stemness of A549 cells. In addition, the inductive effect of hypoxia is 
stronger than TGF-β1, and the combination of both is stronger than either alone, which is first report of such a finding, 
to our knowledge.
Conclusions: Increased TGF-β1 and strengthened hypoxia in A549 transplantation tumors, as a result of ES therapy, 
cooperatively increase proportion of CSCs that are involved in ES resistance which was revealed by failure of tumor 
volume repression after continuously treatment with ES for 12 days.
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Background
Currently, lung cancer is the leading cause of morbid-
ity and mortality from cancer, accounting for 30 % of all 
cancer-related deaths [1]. Although major steps forward 
in the development of a cure for lung cancer have been 
made, many patients still die within a few years after 
diagnosis. Among these cures, anti-angiogenic therapies 
have been found to be relatively short-lived, and most 
patients treated with it eventually relapse and progress. 
The primary explanation for this failure is considered to 
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Endostatin (ES) is a widely-used endogenous, broad-
spectrum, anti-angiogenic inhibitor, and has been shown 
to be clinically effective in China. A number of independ-
ent studies researching into the mechanisms underly-
ing the anti-tumor activities of ES have shown that the 
drug restrains tumor growth through various chan-
nels, including repressing combination between vascu-
lar endothelial growth factor (VEGF) and endothelial 
cells (ECs), initiating EC apoptosis [3], and bonding to 
cell surface receptors such as nucleolin [4] to regulate a 
myriad of signaling cascades. Recently, ES was found to 
be an inhibitor of androgen receptor and could be a new 
choice for castration-resistant prostate cancer [5], and 
it is also a suppressor of basic fibroblast growth factor-
induced angiogenesis in melanoma [6]. However, we have 
recently reported resistance to ES in tumor-bearing mice 
[7], therefore, identifying the reason for this resistance in 
order to overcome-this problem is important. We have 
shown that CD11b+Gr1+ myeloid-derived suppressor 
cells (MDSCs) are involved in resistance to ES [8], but 
further studies are needed to identify whether there are 
other underlying reasons as well.
Recent research has shown that, both cells and cell fac-
tors, inside the tumor microenvironment are directly or 
indirectly involved in drug resistance, including cells such 
as T-regulatory cells (Tregs) [9], cancer stem cells (CSCs) 
[10], tumor-associated fibroblasts (TAFs) [11], and tumor-
associated microphages (TAMs) [12], and cell factors such 
as transforming growth factor (TGF)-β1 [13], hypoxia-
inducible factor (HIF)-1α [14], interleukin (IL)-17 [15], 
IL-6 [16], IL-8 [17], IL-10 [18], and tumour necrosis factor 
(TNF)-α [19]. Whether these cells or cell factors are also 
responsible for resistance to ES needs to be further stud-
ied. Primarily, CSCs, which have drawn extensive  atten-
tion in recent years, should be particularly considered.
The CSC model was proposed in 1997, with the dis-
covery of stem cells in leukemia [20], and evidence of the 
existence of lung CSCs (LCSCs) was shown by Giangreco 
in 2009 [21]. CSCs, which are also known as tumor-initi-
ating cells and stem-like cancer cells, are a subpopulation 
of tumor cells that have been shown into have the prop-
erties of immortal production, self-renewal, and tumor 
formation in xenograft mouse models. CSCs have been 
shown to be involved in tumor growth, metastasis, and 
tumor relapse [22]. CSCs also taken part in drug resist-
ance through a number of different mechanisms. For 
example, CSCs spend the majority of their time in the G0 
phase of the cell cycle, thus anti-neoplastic drugs, which 
act on cycling cell populations, are inefficient against 
CSCs [23]. Conducting research on CSCs is important, 
and the first step in this is identification and separation 
of CSCs from other ‘ordinary’ tumor cells, which has 
been thoroughly researched. For some kinds of leukemia, 
widely acceptable protein markers have been discovered, 
but it is still unclear which markers are the best for lung 
cancer. The majority of studies have shown that CD133+ 
cells, ALDH+ cells, and SP (side population) cells contain 
many more stem cell-like cells, therefore, these three cell 
markers are usually used to identify and sort LCSCs.
We speculated that CSCs are involved in resistance to 
ES, and that treatment with ES will lead to an increase 
of CSCs in lung cancer, resulting in resistance. This study 
aimed to assess the numbers of CSCs in lung cancer after 
treatment with ES and explore reasons of this change.
Results
ES increased the proportion of cancer stem cells in A549 
transplantation tumors
FACS and IHC were used to assess the difference in the 
expression of CSC-related protein (ALDH and CD133) 
between the NS and ES groups. Considering that ALDH 
or CD133 is feasible being used as protein markers to 
identify LCSCs in A549 cells has been shown by large 
amounts of studies [24–30], We also chosen ALDH and 
CD133 as markers of CSC in our present study. Flow 
cytometry shown that there were more CSCs in the 
tumors in the ES group. IHC showed that the propor-
tion of ALDH+ (P = 0.0292*) and CD133+ (P = 0.3265) 
cells were increased in the ES group compared with the 
NS group. There were also more ALDHA1+ (an isoform 
aldehyde dehydrogenase of ALDH) cells in tissue  sec-
tions from the ES group (Fig.  1). Higher proportions of 
ALDH+, CD133+ and ALDHA1+ cells in ES group indi-
cated that LCSCs increased after ES treatment.
ES intensified hypoxia and improved secretion of TGF‑β1 
in A549 transplantation tumor
Anti-angiogenic agents work mainly by suppressing vascu-
larization to decrease blood supply to the tumor and arrest 
its growth. In this present study, immunohistochemi-
cal expression of CD31 and CD105 were utilized to test 
changes of microvessel density (MVD) for CD31, as we all 
know, was expressed constitutively on the surface of ECs 
and is widely used to quantify MVD. CD105 was also cho-
sen because it shown great specificity for the tumor vas-
culature, which is only expressed in the ECs of the tumor 
blood vessel, without being present in the normal ECs [31], 
and also was a prominent feature of newly formed blood 
vessels, but rarely expressed in pre-existing tumor vessels 
[32]. The IHC study showed that CD31+ and CD105+ cells 
were reduced in ES group, indicating that MVD declined 
in A549 transplantation tumors after ES treatment. VEGF 
(detected by VEGF ELISA kit) also decreased, whereas 
HIF-1α in the same tissue was shown by immunofluores-
cence to be increased (Fig. 2). These results agree with our 
previous studies [33]. Hypoxia is indeed involved in the 
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induction of CSC, but whether it can directly enhance the 
stemness of A549 cells needs further study.
To explore more elements relevant to increased LCSC, 
we detected some major cell types and inflammation 
factors in A549 transplantation tumor tissues, and 
discovered that TGF-β1 was significantly  increased 
(P = 0.0217*). Other factors, including TNF-α, IL-6, and 
IL-10, were also increased, although these increases were 
Fig. 1 The proportion of cancer stem cells in A549 transplantation tumors after 12 days of treatment. a Change in tumor volumes after endostatin 
(ES) or normal saline (NS) treatment. b ALDHA1 expression in ES and NS groups. c Flow cytometry showing that ALDH-positive rate was higher in 
the ES group. *P < 0.05 compared with NS group. CD133 positive cell amount is also higher in ES group and the difference does not reach statistical 
significance
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not statistically significant (Fig.  3). We speculate that 
TGF-β1 may be connected with the increase in CSCs in 
the ES group, but further studies are required to confirm 
this.
TGF‑β1 and hypoxia cooperatively increased CSCs
We further assessed whether hypoxia and TGF-β1 take 
part in CSC induction directly, and whether they act 
independently or cooperatively. CoCl2, which is frequent-
used and widely accepted as chemical hypoxia-induced 
agent to mimic hypoxia [34–36] was applied to mimic 
hypoxia in vitro. We treated A549 cells with CoCl2, with 
the human recombinant TGF-β1, and with the combi-
nation of both TGF-β1 and CoCl2. We found that both 
hypoxia and TGF-β1 could enhance the stemness of 
A549 cells. The induction effect of hypoxia was stronger 
than that of TGF-β1, and when both were combined, the 
effect was stronger still, implying that there is crosstalk 
between hypoxia and TGF-β1.
We further measured the amount of protein exchange 
in several commonly accepted signaling pathways 
concerning CSCs and in Smad pathways after treat-
ment as above, and the result showed that expression of 
Notch1, β-catenin, P-Smad2, and P-Smad3 were all ele-
vated (Figs. 4, 5).
MDSCs, and TAM2 were increased in A549 transplantation 
tumor after ES treatment
We assessed whether MDSC and TAM also rose after 
ES treatment of A549 transplantation tumor in NOD/
SCID mice. We assessed TAM2 rather than TAM 
because of its closer relationship with immune suppres-
sion in tumors. In addition, as two of the major sources 
of TGF-β1, MDSC and TAM2 may induce CSCs indi-
rectly. Our study showed that both CD11b+Gr1+MDSCs 
(P  =  0.0026**) and CD11b+F4/80+CD206+TAM2 
(P =  0.6475) increased in the ES group compared with 
the NS group.
Discussion
In this study, we showed that after continuously 
treatment with ES for 12  days, volumes of A549 
Fig. 2 MVD, oxygen concentration, and VEGF level in A549 transplantation tumors after 12 days of treatment. a CD31 and CD105 expression in 
A549 transplantation tumors with endostatin (ES) or normal saline (NS) treatment for 8 days. Positive rate was lower in the ES than in the NS group. 
**P < 0.001 compared with NS group. CD105 expression was also lower in the ES group, although this was not statistically significant. b HIF-1α 
expression in ES and NS groups. c VEGF level was lower in the ES group, although this was not statistically significant
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transplantation tumors of mice reached the sizes of 
tumors which were borne by mice that were treated with 
normal saline (NS) and this meant that resistance to ES 
appeared. CSCs, which have been widely accepted as one 
of reasons responsible for resistance to many anti-tumor 
drugs were also being discovered increased proportion-
ally in A549 transplantation tumors after ES treatment 
for 12  days. In addition, intensified hypoxia, and pro-
moted TGF-β1secretion were also observed. To further 
explore the relationship between CSCs, hypoxia, and 
TGF-β1, we assessed the effect of hypoxia and TGF-β1 
on A549 cells in vitro, and verified that hypoxia and TGF-
β1 are capable of inducing CSCs independently, as the 
proportion of CSCs in A549 cells increased when they 
were treated with CoCl2 and recombinant human TGF-
β1 separately. We also found that treatment with both 
hypoxia and TGF-β1 enhanced CSCs induction, which 
was related to greater activation of Notch1, Smad2, and 
Smad3 in A549 cells. Finally, we found that MDSCs, a 
source of TGF-β1, increased in the A549 transplantation 
tumor model, and this might be one explanation for ele-
vation of TGF-β1 level in tumors.
Research in recent years has shown that tumor stem 
cells are responsible for failure of anti-angiogenesis treat-
ment in cancer. Metastasis is one of the reasons for drug 
resistance. Studies have shown that the number of CSCs 
closely correlates with tumor metastasis [37], with more 
CSCs being found in lymph node metastases than in pri-
mary tumors [38]. CSCs are also involved in angiogenesis 
and lymphangiogenesis because they express angiogenic 
and lymphangiogenic factors. Furthermore, CSCs can 
even differentiate into ECs to promote metastasis of can-
cers. One study found that when culture on Matrigeld in 
the presence of VEGF, breast tumor stem cells could turn 
into ECs and organize into capillary-like structures after 
6  h of culture [39]. All of these phenomena are related 
to the complex tumor microenvironment, as many of 
its components, such as IL-6, HIF-1α, and TGF-β, are 
concerned with induction and maintenance of CSCs. 
Hypoxia is especially important, and is an independ-
ent prognostic factor correlated with advanced stages of 
malignant tumors. As an essential feature of the tumor 
microenvironment, hypoxia is vital in drug resistance. 
Studies have shown that one of the mechanisms of resist-
ance is the capability of hypoxia to inhibit tumor cell dif-
ferentiation and promote maintenance of CSCs [40].
TGF-β is a member of the TGF-β superfamily. It is well 
known that TGF-β plays a dual role in tumorigenesis, 
acting as a suppressor during tumor initiation or in the 
early stages, but as a promoter during cancer progression 
and metastasis in the more advanced stages. TGF-β has 
also been shown to be involved in immune suppression, 
epithelial–mesenchymal transition (EMT) promotion, 
and angiogenesis induction. In addition, TGF-β has been 
shown to stimulate the differentiation of mesenchymal 
precursors into myofibroblasts and thus contribute to 
the generation of CAFs. Furthermore, TGF-β also plays 
an important role in induction and maintenance of CSCs. 
Mani et al. found that TGF-β signaling was necessary for 
maintenance of the stem cell-like properties and tumo-
rigenic activity of tumor cells through induction of EMT. 
TGF-β1 and versican are involved in the molecular mech-
anism of tumor sphere formation TGF-β1 is a triggering 
molecule and stimulates versican [41], and our study also 
showed that versican is involved in resistance to ES [7]. 
A close relationship exists between hypoxia and CSCs 
and many studies have shown that intratumoral hypoxia 
enhances cell stemness in various cancers, including lung 
adenocarcinomas [42], laryngeal cancers [43], pancreatic 
cancers [44], and glioblastomas [45]. There are a number 
of possible underlying mechanisms. First, hypoxia pro-
motes activation of genes and increases levels of proteins 
involved with stem cells, such as activation of insulin-like 
growth factor 1 receptor [46], HIF-1α [47], and the DLK1 
gene [48], and up-regulation of OCT3/4 and SOX2 [49]. 
Secondly, hypoxia can affect CSCs through its impact 
on CSC niches. Hypoxia plays an important role in the 
composition of tumor-associated stromal cells and the 
Fig. 3 Levels of major inflammatory factors elevated after endostatin 
treatment: a IL-6, b IL-10, c TNF-α and d TGF-β1. *P < 0.05 compared 
with NS group
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evolution of tumor stroma, and leads to enrichment 
of undifferentiated stromal cells, which may provide a 
favorable microenvironment for maintaining tumor cells 
in a stem cell state. Finally, hypoxia also regulates expres-
sion of paracrine factors by ECs and other cells for the 
maintenance of CSCs [50]. Hypoxia should be consid-
ered when studies on tumor improvement are being 
conducted.
Utilization of anti-angiogenesis drugs will lead to inten-
sified hypoxia, and increase in cell factors and inflamma-
tion factors, such as TGF-β1. TGF-β1and hypoxia have 
been shown to be involved separately in resistance to 
different kinds of anti-tumor agents. However, there are 
only a few studies reporting on whether these two factors 
act cooperatively, and for more detailed aspects, such as 
anti-angiogenesis drug-resistance, the effect of the com-
bination has not been assessed. According to some stud-
ies, a close link exists between hypoxia and TGF-β1, and 
the effect they have on tumor promotion mainly includes 
three aspects. (1) Immunosuppression: hypoxia can pro-
mote the release of TGF-β1 by inducing IL-19 secretion 
[51, 52], and TGF-β1 derived from induction of hypoxia 
will increase the proportion of T-regs, resulting immun-
suppression [53]. (2) Metastasis: in breast cancer, hypoxia 
and TGF-β1work synergistically to promote secretion of 
VEGF and stromal derived factor 1 receptor (CXCR4), 
and inhibition of either the HIF-1α or the TGF-β path-
way in tumor cells was shown to decrease bone metas-
tasis and improve survival rates, with no further effect of 
double blockade, while, unlike molecular blockade, com-
bined drug treatment decreased bone metastases more 
than either alone [54]. Hypoxia can also improve secre-
tion of TGF-β1 from mesenchymal stem cells to increase 
the invasiveness of breast cancer cells [55]. (3) CSCs: 
hypoxia and TGF-β1 improve transcription and maintain 
stemness of hematopoietic stem cells by acting on the 
CDKN1C/p57 gene, and hypoxia can increase the sen-
sitivity of hematopoietic stem cells to TGF-β1. The cell 
Fig. 4 Effects of hypoxia and TGF-β1 on the ALDH-positive cell proportion of A549 cell cultures. a Hypoxia, TGF-β1, or the combination of both all 
led to a higher ALDH-positive proportion. Induction by hypoxia was stronger than that by TGF-β1, and the combination was stronger than either 
factor alone. *P < 0.05, **P < 0.01, ****P < 0.001. b Hypoxia and TGF-β1 did not cause apoptosis of A549 cells at 24, 36, or 48 h. c Protein expression 
of the related signaling pathway proteins Notch1, P-Smad2, and P-Smad3 were elevated
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cycle pause, an important property of stem cells that is 
induced by TGF-β1, relies on hypoxia [56]. In the current 
study, we found that hypoxia and TGF-β can also induce 
CSCs formation cooperatively, which is the first such 
report, to our knowledge.
Along with MDSCs, TAM is a source of TGF-β1. TAM 
induces tumor cells turning into CSCs by secretion of 
TGF-β1 [57]. MDSCs can produce various immunosup-
pressive factors, including TGF-β1 [58]. In tumor-bear-
ing mice, MDSC can express membrane-bound TGF-1 to 
suppress anti-tumor immunity [59].
In this study, we have shown that ES can increase CSC 
formation, and increased numbers of CSCs are one of the 
reasons for ES resistance which was revealed by failure of 
tumor volume repression after continuously treatment 
with ES for 12 days. To be more detailed, ES strengthens 
hypoxia in tumor tissue and improves secretion of TGF-
β1by activating Smad2, Smad3, β-catenin and Notch1. 
Hypoxia and TGF-β1 increase CSC induction. We also 
found that MDSC, a source of TGF-β1, was increased in 
A549 transplantation tumors.
Conclusions
Our results indicate that increased TGF-β1 and strength-
ened hypoxia in A549 transplantation tumors, as a result 
of ES therapy, cooperatively increase proportion of CSCs 
which are involved in ES resistance which was revealed 
by failure of tumor volume repression after continuously 
treatment with ES for 12 days.
Methods
Tumor cell culture and treatment
The A549 cell line was obtained from the American Type 
Culture Collection (ATCC, Manassas, VA, USA). Cells 
were cultured in Dulbecco’s modified Eagle’s medium 
(Life Technologies, Bedford, MA, US) containing 10  % 
heat-inactivated fetal bovine serum, 100 units/mL peni-
cillin, and 100 units/mL streptomycin in a humid cham-
ber at 37 °C with 5 % CO2. At 75 % confluence, the cells 
were harvested using 0.25  % trypsin, and subcultured 
in 75 cm2 flasks or six-well plates. Cells were allowed to 
attach to the substrate for 24  h before treatment. After 
serum starvation for another 24  h, four different treat-
ments were used: (1) 10  ng/mL human recombinant 
TGF-β1 (Biolegend,San Diego, USA), (2) 100  µmol/L 
cobalt chloride (CoCl2), (3) a combination of both 10 ng/
ml TGF-β1 and 100 µmol/L CoCl2, and the same amount 
of PBS as for the control group. Treatment lasted for 0, 
24, 36, or 48  h separately, and then cells were collected 
for flow cytometry and western blotting.
Animal tumor models and treatment
NOD/SCID mice (female, 5–6  weeks old; Beijing HFK 
Bioscience Co. Ltd, Beijing, China) were maintained in 
the Laboratory for Animal Experiments of Sichuan uni-
versity under specified pathogen-free conditions with 
animal food and water. The mice were injected subcu-
taneously into the right axillary fossa with A549 cells 
(5  ×  106/100  µl). When tumors were palpable and had 
Fig. 5 Endostatin treatment increased tumor-associated macrophages in A549 transplantation tumors. a Flow cytometry showed an increase in 
MDSCs in the ES group; *P < 0.05 compared with the NS group. b TAM2 in the ES group also increased, although this difference did not reach statis-
tical significance. c Immunohistochemistry results showed that CD68 and Gr1 expression was stronger in the ES group compared with the NS group
Page 8 of 10Wang et al. Cell Biosci  (2015) 5:72 
reached approximately 500–650  mm3, at 7–10  days 
after inoculation, mice were randomly assigned into 
treatment and control groups with seven mice in each 
group. Treatments were given via tail vein injection. In 
this research, we utilized NS or ES for the treatment of 
NOD/SCID mice carrying A549 transplantation tumors 
for 12 days. This time point was chosen because ES has 
been shown to fail in tumor suppression at around this 
time. For the treatment (ES) group, 12.5  mg/kg ES was 
injected, and the control (NS) group was given the same 
amount of NS. The drug dosage was in accordance with 
the FDA human–mouse equivalent dosage conversion 
(FDA Guidance for Industry and Reviewers, 2002; FDA 
Guidance for Industry Food-Effect Bioavailability and 
Fed Bioequivalence studies, 2002). At day 12, all mice 
were euthanized, and tumors were immediately collected 
for flow cytometry, enzyme-linked immunosorbent assay 
(ELISA), and immunohistochemistry (IHC). All proce-
dures involving animals were approved by the Animal 
Care and Use Committee of Sichuan University.
Flow cytometry
The A549 tumors taken from the NOD/SCID mice were 
washed with ice-cold phosphate-buffered saline (PBS) pH 
7.4 to remove any remaining blood, and then dissociated 
by mincing the tissue with scalpels, followed by addi-
tion of DMEM medium containing 1 mg/ml collagenase 
I and incubation for 60–90  min at 37 ℃. Incompletely 
dissociated tissue was digested a second time using the 
same procedure. The dissociated tumor tissue was then 
washed with ice-cold PBS and filtered through a 70-μm 
cell strainer (BD Bioscience). The cell suspension was 
then centrifuged at a speed of 1000 rpm for 5 min at 4 ℃. 
The cells were resuspended in PBS for further analysis.
The treated cultured A549 cells were harvested and 
then washed twice with ice-cold PBS.
An Aldefluor kit (StemCell Technologies, Vancouver, 
CA, USA) was used to analyze the population of cells 
with positive aldehyde dehydrogenase (ALDH) enzy-
matic activity. The prepared cells from both the A549 
cell line and the A549 tumors were resuspended in Alde-
fluor assay buffer containing ALDH substrate, Bodipy™-
aminoacetaldehyde (BAAA), 1 µM and incubated at 37 ℃ 
for 30 min according to the manufacturer’s protocol.
For assessment of CD133, CD11b, Gr1, CD206, and 
F4/80 expression in single cells from A549 tumors, cells 
were washed twice with PBS to remove remaining FBS 
or other impurities, and counted to make sure the cell 
number in each test was between 2 ×  105 and 1 ×  106. 
Cells were then resuspended in 100 μL PBS, and primary 
antibody [PE-CD133/AC133 (Miltenyi Biotec, Bergisch 
Gladbach, Germany), PE-Cyanine7-CD11b, APC-Gr1, or 
PE-F4/80 (all ebioscience, Vienna, Austria)] was added. 
Cells treated with CD133 antibody were placed on ice 
and incubated for 10 min. Cells treated with other fluo-
rescence-labeled monoclonal antibodies were placed at 
room temperature in accordance with the manufacturers’ 
instructions, and incubated in the dark for 30 min. Cells 
were then rewashed with PBS and resuspended in 400–
500  µl PBS, then separated in a cell sorter (FACS Aria 
SORP, BD Biosciences, Erembodegem, Belgium).
Enzyme‑linked immunosorbent assay
The samples collected from A549 tumors were ground 
into powder with liquid nitrogen in grinding bowls, and 
then homogenized in radioimmunoprecipitation assay 
(RIPA) buffer (0.1  % SDS, 0.5  % deoxycholate, 1  % Tri-
ton X-100, 150  mM NaCl, and 50  mM Tris–HCl), fol-
lowed by centrifugation at 13,300 rpm for 30 min at 4 ℃. 
DEAB assay was used to test the protein concentration 
of samples. The prepared samples were stored at 80 ℃ 
until used. Levels of TNF-α, TGF-β, IL-6, and IL-10 in 
the samples were assessed by mouse ELISA kits (eBiosci-
ence or R&D Systems, Minneapolis, MN, USA) according 
to the manufacturer’s instructions, and the colorimet-
ric reaction was measured at 450 nm using a microplate 
reader (Benchmark Electronics, Angleton, TX, USA).
Immunohistochemical and immunoflorescence analysis
Tumors from NOD/SCID mice were immediately fro-
zen and sliced into 5  μm sections. ALDHA1 (aldehyde 
dehydrogenase 1 family, member A1) expression was 
determined by anti-ALDHA1 antibody (Abcam) immu-
nostaining. MVD was determined by rat anti-mouse 
CD31 (Biolegend) immunostaining, and TAMs were 
assessed by rabbit anti-mouse CD68 and rabbit anti-
mouse Gr1 expression. Frozen sections were incubated in 
3 % H2O2 and blocked with 5 % bovine serum albumin. 
The sections were then incubated with the relevant anti-
bodies (diluted as instructions advised) at 4 ℃ overnight, 
followed by incubation with goat anti-rabbit or goat anti-
rat antibody (diluted 1:500). Peroxidase activity was visu-
alized using 3,3′-diaminobenzidine (DAB) substrate kit 
(Beyotime Bioscience, Shanghai, China). Sections were 
counterstained with hematoxylin. Slides were examined 
using a microscope (Eclipse E600; Nikon, Tokyo, Japan).
Western blotting
A549 cells were harvested as described above. Total pro-
tein was quantified with Micro BCA Protein Assay Kit 
(Pierce, USA). Total protein (10  μg) from each sample 
was separated by electrophoresis using 12 % SDS-PAGE 
gels, and transferred onto PVDF membranes, blocked 
with 5  % skim milk (Merck), and incubated using the 
primary antibodies (1:1000) overnight at 4 ℃. The cor-
responding secondary antibodies (1:10,000) were applied 
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for 1 h at room temperature. Glyceraldehyde 3-phophate 
(GAPDH) was used as a loading control. Signals were 
developed on X-ray films following exposure to ECL 
advanced luminescence.
Statistical analysis
Data are expressed as mean  ±  SD. Statistical analyses 
were performed using the Statistical Package for the 
Social Sciences (version 16.0; SPSS Inc., Chicago, IL, 
USA). Between-group statistical significance was deter-
mined using Student’s t test. Significance was set at 
P < 0.05.
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